Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 1 of 20 PageID: 1
`
`Stephen M. Hash
`VINSON & ELKINS LLP
`2801 Via Fortuna, Suite 100
`Austin, TX 78746-7568
`(512) 542-8400
`
`Of Counsel for Plaintiff Pozen Inc.
`
`
`
`
`
`
`
`John E. Flaherty
`Jonathan M.H. Short
`McCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry Street
`Newark, New Jersey 07102
`(973) 622-4444
`
`Attorneys for Plaintiffs Horizon Pharma, Inc.
`and Pozen Inc..
`
`Ricardo Rodriguez
`COOLEY LLP
`3175 Hanover Street
`Palo Alto, CA 94304-1130
`(650) 843-5000
`
`Of Counsel for Plaintiff Horizon Pharma, Inc.
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF NEW JERSEY
`
`
`Civil Action No. _____________________
`
`COMPLAINT FOR PATENT
`INFRINGEMENT AND
`CERTIFICATION PURSUANT TO
`LOCAL CIVIL RULE 11.2
`
`
`
`
`
`
`
`
`HORIZON PHARMA, INC. and POZEN INC.,
`
`Plaintiffs,
`
`v.
`
`
`MYLAN PHARMACEUTICALS INC.,
`MYLAN LABORATORIES LIMITED, and
`MYLAN, INC.,
`
`
`Defendants.
`
`
`
`
`
`
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 2 of 20 PageID: 2
`
`
`
`Plaintiffs Horizon Pharma, Inc. and Pozen Inc. (collectively, “Plaintiffs”), by their
`
`attorneys, for their Complaint against Mylan Pharmaceuticals Inc., Mylan Laboratories Limited,
`
`and Mylan, Inc. (collectively, “Defendants”), allege as follows:
`
`THE PARTIES
`
`1.
`
`Plaintiff Horizon Pharma, Inc. (“Horizon”) is a corporation operating and existing
`
`under the laws of the State of Delaware, with its principal place of business at 520 Lake Cook
`
`Road, Suite 520, Deerfield, Illinois 60015.
`
`2.
`
`Plaintiff Pozen Inc. (“Pozen”) is a corporation operating and existing under the
`
`laws of the State of Delaware, with its principal place of business at 1414 Raleigh Road, Chapel
`
`Hill, North Carolina 27517.
`
`3.
`
`On information and belief, Defendant Mylan Pharmaceuticals Inc. is a corporation
`
`organized and existing under the laws of the State of West Virginia, with its principal place of
`
`business at 781 Chestnut Ridge Rd., Morgantown, West Virginia 26505. On information and
`
`belief, Mylan Pharmaceuticals Inc. is in the business of, inter alia, manufacturing, marketing,
`
`and selling generic copies of branded pharmaceutical products throughout the United States,
`
`including within this district.
`
`4.
`
`.On information and belief, Defendant Mylan Laboratories Limited (“Mylan
`
`Limited”) was formerly known as Matrix Laboratories Limited (“Matrix Limited”). On
`
`information and belief, Defendant Mylan Limited is a corporation organized and existing under
`
`the laws of India, with its principal place of business at Plot No. 564/A/22, Road No. 92,
`
`Hyderabad 500034 Andhra Pradesh, India. On information and belief, Mylan Limited is in the
`
`business of, inter alia, manufacturing, marketing, and selling generic copies of branded
`
`pharmaceutical products throughout the United States, including within this district.
`
`
`
`1
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 3 of 20 PageID: 3
`
`
`
`5.
`
`On information and belief, Defendant Mylan, Inc. is a corporation organized and
`
`existing under the laws of Pennsylvania, with its principal place of business at 1000 Mylan
`
`Blvd., Canonsburg, Pennsylvania 15317. On information and belief, Mylan, Inc. is in the
`
`business of, inter alia, manufacturing, marketing, and selling generic copies of branded
`
`pharmaceutical products throughout the United States, including within this district.
`
`6.
`
`On information and belief, Mylan, Inc. is the parent company of Mylan
`
`Pharmaceuticals Inc.
`
`7.
`
`8.
`
`On information and belief, Mylan, Inc. is the parent company of Mylan Limited.
`
`On information and belief, Mylan Pharmaceuticals Inc. and Mylan Limited are
`
`within the control of Defendant Mylan, Inc. for purposes of responding to discovery in this
`
`action.
`
`BACKGROUND
`
`The NDA
`
`9.
`
`Horizon is the holder of New Drug Application (“NDA”) No. 022511 for
`
`VIMOVO® (naproxen and esomeprazole magnesium) Delayed-Release Tablets, in 375 mg
`
`(naproxen)/20 mg (esomeprazole magnesium) and 500 mg (naproxen)/20 mg (esomeprazole
`
`magnesium) dosage forms.
`
`10.
`
`VIMOVO® Delayed-Release Tablets are prescription drugs approved for use to
`
`relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
`
`and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach
`
`ulcers from treatment with non-steroidal anti-inflammatory drugs (NSAIDs). Naproxen and
`
`esomeprazole magnesium are the active ingredients in VIMOVO® Delayed-Release Tablets.
`
`
`
`2
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 4 of 20 PageID: 4
`
`
`
`The Patents-in-Suit
`
`11.
`
`United States Patent No. 8,852,636 (“the ’636 patent”), entitled “Pharmaceutical
`
`Compositions for the Coordinated Delivery of NSAIDs” was duly and legally issued by the
`
`United States Patent and Trademark Office on October 7, 2014. The claims of the ’636 patent
`
`are directed to pharmaceutical compositions in unit dosage form comprising esomeprazole and
`
`naproxen (claims 1–4, 7–10, 13–18) and methods of treating a patient for pain or inflammation
`
`comprising administration of the aforementioned compositions (claims 5–6, 11–12). A true and
`
`correct copy of the ’636 patent is attached as Exhibit A.
`
`12.
`
`Pozen owns the ’636 patent by assignment. Horizon is Pozen’s exclusive licensee
`
`under the ’636 patent. The ’636 patent will expire on May 31, 2022.
`
`13.
`
`The ’636 patent is listed in the FDA Orange Book in connection with NDA No.
`
`022511 for VIMOVO® Delayed-Release Tablets.
`
`14.
`
`United States Patent No. 8,858,996 (“the ’996 patent”), entitled “Pharmaceutical
`
`Compositions for the Coordinated Delivery of NSAIDs,” was duly and legally issued by the
`
`United States Patent and Trademark Office on October 14, 2014. The claims of the ’996 patent
`
`are directed to pharmaceutical compositions in unit dosage form comprising esomeprazole and
`
`naproxen (claims 1–9, 12–15) and methods of treating a patient for pain or inflammation
`
`comprising administration of the aforementioned compositions (claims 10–11, 16–19). A true
`
`and correct copy of the ’996 patent is attached as Exhibit B.
`
`15.
`
` Pozen owns the ’996 patent by assignment. Horizon is Pozen’s exclusive
`
`licensee under the ’996 patent. The ’996 patent will expire on May 31, 2022.
`
`16.
`
`The ’996 patent is listed in the FDA Orange Book in connection with NDA No.
`
`022511 for VIMOVO® Delayed-Release Tablets.
`
`
`
`3
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 5 of 20 PageID: 5
`
`
`
`Related Patents
`
`17.
`
`United States Patent No. 6,926,907 (“the ’907 patent”), entitled “Pharmaceutical
`
`Compositions for the Coordinated Delivery of NSAIDs,” was duly and legally issued by the
`
`United States Patent and Trademark Office on August 9, 2005. The claims of the ’907 patent are
`
`directed to pharmaceutical compositions that provide for the coordinated release of an acid
`
`inhibitor and an NSAID (claims 1–21, and 53–55) and methods of treating a patient for pain or
`
`inflammation comprising administration of the aforementioned compositions (claims 22–52).
`
`18.
`
`Pozen owns the ’907 patent by assignment. Horizon is Pozen’s exclusive licensee
`
`under the ’907 patent. The ’907 patent will expire on February 28, 2023.
`
`19.
`
`The ’907 patent is listed in the FDA Orange Book in connection with NDA No.
`
`022511 for VIMOVO® drug product.
`
`20.
`
`United States Patent No. 8,557,285 (“the ’285 patent”), entitled “Pharmaceutical
`
`Compositions for the Coordinated Delivery of NSAIDs,” was duly and legally issued by the
`
`United States Patent and Trademark Office on October 15, 2013. The claims of the ’285 patent
`
`are directed to pharmaceutical compositions in unit dosage form comprising esomeprazole and
`
`naproxen.
`
`21.
`
`Pozen owns the ’285 patent by assignment. Horizon is Pozen’s exclusive licensee
`
`under the ’285 patent. The ’285 patent will expire on May 31, 2022.
`
`22.
`
`The ’285 patent is listed in the FDA Orange Book in connection with NDA No.
`
`022511 for VIMOVO® drug product.
`
`The ANDA
`
`23.
`
`On information and belief, Defendants filed ANDA No. 204920 (“Defendants’
`
`ANDA”) with the FDA under 21 U.S.C. § 355(j) to obtain FDA approval for the commercial
`
`
`
`4
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 6 of 20 PageID: 6
`
`
`
`manufacture, use, import, offer for sale, and sale in the United States of naproxen and
`
`esomeprazole magnesium delayed-release tablets in 375 mg (naproxen)/20 mg (esomeprazole
`
`magnesium) and 500 mg (naproxen)/20 mg (esomeprazole magnesium) strengths (“Mylan’s
`
`ANDA Product”), which are generic versions of Plaintiffs’ VIMOVO® Delayed-Release Tablets
`
`in 375 mg (naproxen)/20 mg (esomeprazole magnesium) and 500 mg (naproxen)/20 mg
`
`(esomeprazole magnesium) strengths, respectively.
`
`24.
`
`By letter dated May 16, 2013 (the “ANDA Notice Letter”), Defendants notified
`
`AstraZeneca AB (Horizon’s predecessor-in-interest as holder of NDA No. 022511 and as
`
`exclusive licensee for the ’907 patent and the ’285 patent) and Pozen that Defendants had filed
`
`ANDA No. 204920 seeking approval to market Mylan’s ANDA Product and that Defendants
`
`were providing information pursuant to 21 U.S.C. § 355(j)(2)(B)(ii) and 21 C.F.R. § 314.95
`
`regarding certain patents including the ’907 patent.
`
`25.
`
`On January 23, 2015, Plaintiffs requested that Defendants provide Paragraph IV
`
`certifications with respect to inter alia the patents in suit.
`
`26.
`
`By three letters each dated February 9, 2015 (the “February ANDA Notice
`
`Letters”), Defendants notified Horizon and Pozen that Defendants had filed ANDA No. 204470
`
`seeking approval to market Actavis’ ANDA Product and that Defendants were providing
`
`information pursuant to 21 U.S.C. § 355(j)(2)(B)(ii) and 21 C.F.R. § 314.95 regarding the ’285,
`
`’636, and ’996 patents.
`
`JURISDICTION AND VENUE
`
`27.
`
`This action arises under the patent laws of the United States, 35 U.S.C. § 1 et seq.,
`
`including 35 U.S.C. § 271, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.
`
`This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).
`
`
`
`5
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 7 of 20 PageID: 7
`
`
`
`28.
`
`On information and belief, Defendants have been and are engaging in activities
`
`directed toward infringement of the ’636 and ’996 patents (collectively, the “patents-in-suit”) by,
`
`inter alia, submitting to the FDA ANDA No. 204920 and continuing to seek approval for
`
`Mylan’s ANDA Product.
`
`29.
`
`Defendants’ ANDA Notice Letter states Defendants’ intention to seek FDA
`
`approval to market a generic version of the VIMOVO® product before the related ’907 patent
`
`expires on February 28, 2023.
`
`30.
`
`There is now an actual controversy between Defendants and Plaintiffs as to
`
`whether Defendants infringe the ’636 and ’996 patents.
`
`31.
`
`This Court has personal jurisdiction over Defendants because, inter alia,
`
`Defendants, on information and belief, have purposely availed themselves of the benefits and
`
`protections of the laws of New Jersey such that they should reasonably anticipate being haled
`
`into court here; Defendants have had continuous and systematic contacts with this judicial
`
`district, including, on information and belief, selling pharmaceutical products in New Jersey and
`
`deriving substantial revenues from those sales; and, on information and belief, Mylan, Inc. and
`
`Mylan Limited are licensed to do business within New Jersey. Thus, Defendants are subject to
`
`general jurisdiction in New Jersey.
`
`32.
`
`On information and belief, Defendants acted in concert to develop Mylan’s
`
`ANDA Product and to seek approval from the FDA to sell Mylan’s ANDA Product throughout
`
`the United States, including within this judicial district.
`
`33.
`
`On information and belief, the acts of Mylan Pharmaceuticals Inc. and Mylan
`
`Limited complained of herein were done at the direction of, with the authorization of, and with
`
`the cooperation, participation, and assistance of Mylan, Inc.
`
`
`
`6
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 8 of 20 PageID: 8
`
`
`
`34.
`
`On information and belief, Mylan Pharmaceuticals Inc., Mylan Limited, and
`
`Mylan, Inc. participated in the preparation and/or filing of ANDA No 204920.
`
`35.
`
`On information and belief and as stated in the ANDA Notice Letter, the FDA
`
`received ANDA No. 204920 from Defendants.
`
`36.
`
`On information and belief, by virtue of, inter alia, Defendants’ continuous and
`
`systematic contacts with New Jersey, including but not limited to the above-described contacts,
`
`and the actions on behalf of Defendants in connection with ANDA No. 204920, this Court has
`
`personal jurisdiction over Defendants. These activities satisfy due process and confer personal
`
`jurisdiction over Defendants consistent with New Jersey law.
`
`37.
`
`Venue is proper in this District under 28 U.S.C. §§ 1391(b), 1391(c), and 1400(b).
`
`COUNT I
`(INFRINGEMENT OF THE ’636 PATENT UNDER 35 U.S.C. § 271(e)(2))
`
`
`
`38.
`
`Plaintiffs incorporate by reference paragraphs 1–37 of this Complaint as if fully
`
`set forth herein.
`
`39.
`
`The ’636 patent is a patent with respect to which a claim of patent infringement
`
`could reasonably be asserted if a person not licensed by the owner engaged in the manufacture,
`
`use, sale, or importation of the VIMOVO® product.
`
`40.
`
`Accordingly, pursuant to 21 U.S.C. § 355(c)(2), Plaintiffs submitted patent
`
`information for the ’636 patent to the FDA in connection with NDA No. 022511 for the
`
`VIMOVO® product. On information and belief, this information will be published in the FDA’s
`
`Orange Book.
`
`41.
`
`21 U.S.C. § 355(j)(2)(A)(vii)(IV) (“Paragraph IV”) requires, inter alia,
`
`certification by the ANDA applicant that the subject patent in the Orange Book, here the ’636
`
`patent, “is invalid or will not be infringed by the manufacture, use, or sale of the new drug for
`
`
`
`7
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 9 of 20 PageID: 9
`
`
`
`which the application is submitted . . . .” The statute (21 U.S.C. § 355(j)(2)(B)(iv)) also requires
`
`a Paragraph IV notice to “include a detailed statement of the factual and legal basis of the
`
`opinion of the applicant that the patent is not valid or will not be infringed.” The FDA Rules and
`
`Regulations (21 C.F.R. § 314.95(c)) specify, inter alia, that a Paragraph IV notification must
`
`include “[a] detailed statement of the factual and legal basis of applicant’s opinion that the patent
`
`is not valid, unenforceable, or will not be infringed.” The detailed statement is to include “(i)
`
`[f]or each claim of a patent alleged not to be infringed, a full and detailed explanation of why the
`
`claim is not infringed” and “(ii) [f]or each claim of a patent alleged to be invalid or
`
`unenforceable, a full and detailed explanation of the grounds supporting the allegation.”
`
`42.
`
`On information and belief, Defendants were aware of the statutory provisions and
`
`regulations referred to in paragraph 41 above when they served the ANDA Notice Letter
`
`regarding certain patents including the ’907 patent.
`
`43.
`
`On information and belief, Defendants have previously filed patent certifications
`
`in association with their ANDA No. 204920 seeking, inter alia, FDA final approval prior to
`
`February 28, 2023. The ’636 patent has an expiration date of May 31, 2022. Therefore, on
`
`further information and belief, Defendants are currently pursuing FDA final approval of ANDA
`
`No. 204920 before the ’636 patent expires.
`
`44.
`
`On information and belief, the making, using, selling, or offering for sale in the
`
`United States or the importation into the United States of Mylan’s ANDA Product infringes the
`
`’636 patent.
`
`45.
`
`Defendants have infringed, either literally or under the doctrine of equivalents, the
`
`’636 patent under 35 U.S.C. § 271(e)(2) by filing ANDA No. 204920 and continuing to seek
`
`
`
`8
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 10 of 20 PageID: 10
`
`
`
`approval from the FDA to engage in the commercial manufacture, use, sale, or importation of a
`
`drug claimed in the ’636 patent before the expiration of the ’636 patent.
`
`46.
`
`On information and belief, Mylan’s ANDA Product contains the pharmaceutical
`
`composition patented in the ’636 patent, is a material for use in practicing the methods patented
`
`in the ’636 patent, constitutes a material part of the inventions of the ’636 patent, is especially
`
`made or especially adapted for use in an infringement of the ’636 patent, and is not a staple
`
`article or commodity of commerce suitable for substantial noninfringing use. On information
`
`and belief, Defendants are aware that Mylan’s ANDA Product is so made or so adapted. On
`
`information and belief, Defendants are aware that Mylan’s ANDA Product, if approved, will be
`
`used in contravention of Plaintiffs’ rights under the ’636 patent.
`
`47.
`
`On information and belief, Defendants’ above-described activities are continuing
`
`and constitute an act of infringement of the ’636 patent under 35 U.S.C. § 271(e)(2).
`
`48.
`
`Plaintiffs will be substantially and irreparably harmed by the infringing activities
`
`described above unless those activities are precluded by this Court. Plaintiffs have no adequate
`
`remedy at law.
`
`
`
`COUNT II
`(DECLARATORY JUDGMENT AS TO THE ’636 PATENT)
`
`49.
`
`Plaintiffs incorporate by reference paragraphs 1–48 of this Complaint as if fully
`
`set forth herein.
`
`50.
`
`The ’636 patent is a patent with respect to which a claim of patent infringement
`
`could reasonably be asserted if a person not licensed by the owner engaged in the manufacture,
`
`use, sale, or importation of the VIMOVO® product.
`
`51.
`
`On information and belief, Mylan’s ANDA Product contains the pharmaceutical
`
`composition patented in the ’636 patent, is a material for use in practicing the methods patented
`
`
`
`9
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 11 of 20 PageID: 11
`
`
`
`in the ’636 patent, constitutes a material part of the inventions of the ’636 patent, is especially
`
`made or especially adapted for use in an infringement of the ’636 patent, and is not a staple
`
`article or commodity of commerce suitable for substantial noninfringing use. On information
`
`and belief, Defendants are aware that Mylan’s ANDA Product is so made or so adapted.
`
`52.
`
`On information and belief, the making, using, selling, or offering for sale in the
`
`United States or the importation into the United States of Mylan’s ANDA Product before the
`
`expiration of the ’636 patent constitutes infringement of the ’636 patent under 35 U.S.C.
`
`§§ 271(a), (b), and/or (c).
`
`53.
`
`On information and belief, Defendants have previously filed patent certifications
`
`in association with their ANDA No. 204920 seeking, inter alia, FDA final approval to market
`
`Mylan’s ANDA Product before February 28, 2023.
`
`54.
`
`The ANDA Notice Letter shows Defendants’ intent to market Mylan’s ANDA
`
`Product before the ’636 patent expires on May 31, 2022.
`
`55.
`
`On information and belief, Defendants continue to seek FDA final approval for
`
`Mylan’s ANDA Product. On information and belief, Defendants are aware that the manufacture,
`
`use, sale, or offer for sale in the United States or the importation into the United States of
`
`Mylan’s ANDA Product, if approved, will infringe the ’636 patent under 35 U.S.C. §§ 271(a),
`
`(b), and/or (c).
`
`56.
`
`On information and belief, Defendants have made, and will continue to make,
`
`substantial preparation to manufacture, use, sell, or offer to sell in the United States or import
`
`into the United States Mylan’s ANDA Product before the ’636 patent expires.
`
`57.
`
`On information and belief, Defendants intend to engage in the commercial
`
`manufacture, use, sale, or offer for sale in the United States or importation into the United States
`
`
`
`10
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 12 of 20 PageID: 12
`
`
`
`of Mylan’s ANDA Product after receiving FDA final approval of ANDA No. 204920 and before
`
`the ’636 patent expires.
`
`58.
`
`Defendants maintain, on information and belief, and Plaintiffs deny that the ’636
`
`patent is invalid or unenforceable and that Mylan’s ANDA Product does not or will not infringe
`
`the ’636 patent. Accordingly, a definite and concrete, real and substantial, justiciable case or
`
`controversy exists between Plaintiffs and Defendants concerning infringement of the ’636 patent
`
`by Mylan’s ANDA Product.
`
`59.
`
`Plaintiffs will be substantially and irreparably harmed by the infringing activities
`
`described above unless those activities are precluded by this Court. Plaintiffs have no adequate
`
`remedy at law.
`
`60.
`
`Plaintiffs are entitled to a declaration that the making, using, sale, or offer for sale
`
`in the United States or the importation into the United States of Mylan’s ANDA Product will
`
`infringe one or more claims of the ’636 patent.
`
`COUNT III
`(INFRINGEMENT OF THE ’996 PATENT UNDER 35 U.S.C. § 271(e)(2))
`
`
`
`61.
`
`Plaintiffs incorporate by reference paragraphs 1–60 of this Complaint as if fully
`
`set forth herein.
`
`62.
`
`The ’996 patent is a patent with respect to which a claim of patent infringement
`
`could reasonably be asserted if a person not licensed by the owner engaged in the manufacture,
`
`use, sale, or importation of the VIMOVO® product.
`
`63.
`
`Accordingly, pursuant to 21 U.S.C. § 355(c)(2), Plaintiffs timely submitted patent
`
`information for the ’996 patent to the FDA in connection with NDA No. 022511 for the
`
`VIMOVO® product. This information has been published in the FDA’s Orange Book.
`
`
`
`11
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 13 of 20 PageID: 13
`
`
`
`64.
`
`21 U.S.C. § 355(j)(2)(A)(vii)(IV) (“Paragraph IV”) requires,
`
`inter alia,
`
`certification by the ANDA applicant that the subject patent in the Orange Book, here the ’996
`
`patent, “is invalid or will not be infringed by the manufacture, use, or sale of the new drug for
`
`which the application is submitted . . . .” The statute (21 U.S.C. § 355(j)(2)(B)(iv)) also requires
`
`a Paragraph IV notice to “include a detailed statement of the factual and legal basis of the
`
`opinion of the applicant that the patent is not valid or will not be infringed.” The FDA Rules and
`
`Regulations (21 C.F.R. § 314.95(c)) specify, inter alia, that a Paragraph IV notification must
`
`include “[a] detailed statement of the factual and legal basis of applicant’s opinion that the patent
`
`is not valid, unenforceable, or will not be infringed.” The detailed statement is to include “(i)
`
`[f]or each claim of a patent alleged not to be infringed, a full and detailed explanation of why the
`
`claim is not infringed” and “(ii) [f]or each claim of a patent alleged to be invalid or
`
`unenforceable, a full and detailed explanation of the grounds supporting the allegation.”
`
`65.
`
`On information and belief, Defendants were aware of the statutory provisions and
`
`regulations referred to in paragraph 64 above when they served the March ANDA Notice Letter
`
`regarding certain patents including the ’907 patent and when they served the November ANDA
`
`Notice Letter regarding the ’285 patent.
`
`66.
`
`On information and belief, Defendants have previously filed patent certifications
`
`in association with their ANDA No. 204470 seeking, inter alia, FDA final approval prior to
`
`February 28, 2023. The ’996 patent has an expiration date of May 31, 2022. Therefore, on
`
`further information and belief, Defendants are currently pursuing FDA final approval of ANDA
`
`No. 204470 before the ’996 patent expires.
`
`67.
`
`Pursuant to 21 U.S.C. § 355(j)(2)(A)(vii), Defendants should file a patent
`
`certification in their pending ANDA No. 204470 with respect to the ’996 patent and must make a
`
`
`
`12
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 14 of 20 PageID: 14
`
`
`
`Paragraph IV certification with respect to the ’996 patent if Defendants continue to seek FDA
`
`final approval of their ANDA No. 204470 before the ’996 patent expires.
`
`68.
`
`On information and belief, the making, using, selling, or offering for sale in the
`
`United States or the importation into the United States of Actavis’ ANDA Product infringes the
`
`’996 patent.
`
`69.
`
`Defendants have infringed, either literally or under the doctrine of equivalents, the
`
`’9966 patent under 35 U.S.C. § 271(e)(2) by filing ANDA No. 204470 and continuing to seek
`
`approval from the FDA to engage in the commercial manufacture, use, sale, or importation of a
`
`drug claimed in the ’996 patent before the expiration of the ’996 patent.
`
`70.
`
`On information and belief, Actavis’ ANDA Product contains the pharmaceutical
`
`composition patented in the ’996 patent, is a material for use in practicing the methods patented
`
`in the ’996 patent, constitutes a material part of the inventions of the ’996 patent, is especially
`
`made or especially adapted for use in an infringement of the ’996 patent, and is not a staple
`
`article or commodity of commerce suitable for substantial noninfringing use. On information
`
`and belief, Defendants are aware that Actavis’ ANDA Product is so made or so adapted. On
`
`information and belief, Defendants are aware that Actavis’ ANDA Product, if approved, will be
`
`used in contravention of Plaintiffs’ rights under the ’996 patent.
`
`71.
`
`On information and belief, Defendants’ above-described activities are continuing
`
`and constitute an act of infringement of the ’996 patent under 35 U.S.C. § 271(e)(2).
`
`72.
`
`Plaintiffs will be substantially and irreparably harmed by the infringing activities
`
`described above unless those activities are precluded by this Court. Plaintiffs have no adequate
`
`remedy at law.
`
`
`
`13
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 15 of 20 PageID: 15
`
`
`
`
`
`COUNT IV
`(DECLARATORY JUDGMENT AS TO THE ’996 PATENT)
`
`73.
`
`Plaintiffs incorporate by reference paragraphs 1–72 of this Complaint as if fully
`
`set forth herein.
`
`74.
`
`The ’996 patent is a patent with respect to which a claim of patent infringement
`
`could reasonably be asserted if a person not licensed by the owner engaged in the manufacture,
`
`use, sale, or importation of the VIMOVO® product.
`
`75.
`
`On information and belief, Actavis’ ANDA Product contains the pharmaceutical
`
`composition patented in the ’996 patent, is a material for use in practicing the methods patented
`
`in the ’996 patent, constitutes a material part of the inventions of the ’996 patent, is especially
`
`made or especially adapted for use in an infringement of the ’996 patent, and is not a staple
`
`article or commodity of commerce suitable for substantial noninfringing use. On information
`
`and belief, Defendants are aware that Actavis’ ANDA Product is so made or so adapted.
`
`76.
`
`On information and belief, the making, using, selling, or offering for sale in the
`
`United States or the importation into the United States of Actavis’ ANDA Product before the
`
`expiration of the ’996 patent constitutes infringement of the ’996 patent under 35 U.S.C.
`
`§§ 271(a), (b), and/or (c).
`
`77.
`
`On information and belief, Defendants have previously filed patent certifications
`
`in association with their ANDA No. 204470 seeking, inter alia, FDA final approval to market
`
`Actavis’ ANDA Product before February 28, 2023.
`
`78.
`
`The March ANDA Notice Letter and the November ANDA Notice Letter show
`
`Defendants’ intent to market Actavis’ ANDA Product before the ’996 patent expires on May 31,
`
`2022.
`
`
`
`14
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 16 of 20 PageID: 16
`
`
`
`79.
`
`On information and belief, Defendants continue to seek FDA final approval for
`
`Actavis’ ANDA Product. On information and belief, Defendants are aware that the manufacture,
`
`use, sale, or offer for sale in the United States or the importation into the United States of
`
`Actavis’ ANDA Product, if approved, will infringe the ’996 patent under 35 U.S.C. §§ 271(a),
`
`(b), and/or (c).
`
`80.
`
`On information and belief, Defendants have made, and will continue to make,
`
`substantial preparation to manufacture, use, sell, or offer to sell in the United States or import
`
`into the United States Actavis’ ANDA Product before the ’996 patent expires.
`
`81.
`
`On information and belief, Defendants intend to engage in the commercial
`
`manufacture, use, sale, or offer for sale in the United States or importation into the United States
`
`of Actavis’ ANDA Product after receiving FDA final approval of ANDA No. 204470 and before
`
`the ’996 patent expires.
`
`82.
`
`Defendants maintain, on information and belief, and Plaintiffs deny that the ’996
`
`patent is invalid or unenforceable and that Actavis’ ANDA Product does not or will not infringe
`
`the ’996 patent. Accordingly, a definite and concrete, real and substantial, justiciable case or
`
`controversy exists between Plaintiffs and Defendants concerning infringement of the ’996 patent
`
`by Actavis’ ANDA Product.
`
`83.
`
`Plaintiffs will be substantially and irreparably harmed by the infringing activities
`
`described above unless those activities are precluded by this Court. Plaintiffs have no adequate
`
`remedy at law.
`
`84.
`
`Plaintiffs are entitled to a declaration that the making, using, sale, or offer for sale
`
`in the United States or the importation into the United States of Actavis’ ANDA Product will
`
`infringe one or more claims of the ’996 patent.
`
`
`
`15
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 17 of 20 PageID: 17
`
`
`
`
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiffs respectfully request the following relief:
`
`A.
`
`B.
`
`A judgment that the claims of the ’636 and ’996 patents are valid and enforceable;
`
`A judgment that the submission of ANDA No. 204920 by Defendants infringes
`
`one or more claims of the’636 and ’996 patents under 35 U.S.C. § 271(e)(2)(A);
`
`C.
`
`A judgment providing that, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective
`
`date of any FDA approval of Defendants’ ANDA No. 204920 shall be no earlier than the
`
`expiration date of the ’636 and ’996 patents or any later exclusivity to which Plaintiffs are or
`
`become entitled;
`
`D.
`
`A judgment pursuant to 35 U.S.C. § 271(e)(4)(B) permanently enjoining
`
`Defendants, and all persons acting in concert with any of them, from making, using, selling,
`
`offering to sell, or importing the naproxen and esomeprazole magnesium product described in
`
`Defendants’ ANDA No. 204920 no earlier than the expiration date of the ’636 and ’996 patents
`
`or any later exclusivity to which Plaintiffs are or become entitled;
`
`E.
`
`F.
`
`A declaration that Defendants have infringed the patents-in-suit;
`
`A declaration that the commercial use, sale, offer for sale, manufacture in the
`
`United States and/or importation into the United States by Defendants of the naproxen and
`
`esomeprazole magnesium product described in Defendants’ ANDA No. 204920 would infringe
`
`the patents-in-suit;
`
`G.
`
`An order preliminarily and permanently enjoining Defendants, and all persons
`
`acting in concert with any of them, from making, using, selling, offering to sell, or importing the
`
`naproxen and esomeprazole magnesium product described in Defendants’ ANDA No. 204920 no
`
`
`
`16
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 18 of 20 PageID: 18
`
`
`
`earlier than the expiration date of the ’636 and ’996 patents or any later exclusivity to which
`
`Plaintiffs are or become entitled;
`
`H.
`
`Attorneys’ fees in this action pursuant to 35 U.S.C. § 285;
`
`Costs and expenses in this action; and
`
`Such further and other relief as this Court may deem just and proper.
`
`I.
`
`J.
`
`
`
`Dated: May 13, 2015
`
`Respectfully submitted,
`
`
`
`By: s/ John E. Flaherty
`John E. Flaherty
`Jonathan M.H. Short
`MCCARTER & ENGLISH, LLP
`Four Gateway Center
`100 Mulberry Street
`Newark, New Jersey 07102
`(973) 622-4444
`
`Counsel for Plaintiffs Horizon Pharma,
`Inc. and Pozen Inc.
`
`Stephen M. Hash
`VINSON & ELKINS LLP
`2801 Via Fortuna, Suite 100
`Austin, TX 78746-7568
`(512) 542-8400
`
`Of Counsel for Plaintiff Pozen Inc.
`
`Ricardo Rodriguez
`COOLEY LLP
`3175 Hanover Street
`Palo Alto, CA 94304-1130
`(650) 843-5000
`
`Of Counsel for Plaintiff Horizon Pharma,
`Inc.
`
`
`
`
`
`
`17
`
`
`
`
`
`
`
`
`
`
`
`

`
`Case 3:15-cv-03327-MLC-DEA Document 1 Filed 05/13/15 Page 19 of 20 PageID: 19
`
`
`
`
`
`CERTIFICATION PURSUANT TO L. CIV. R. 11.2
`
`Pursuant to Local Civil Rule 11.2, I here